Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)

NCT02594267 is registered in ClinicalTrials.gov with Acrotech Biopharma Inc. as lead sponsor.

NCT NCT02594267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02594267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
Lead sponsor
Acrotech Biopharma Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 10, 2015
Completion date
October 8, 2020
Enrollment
48 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma (ptcl)